ARTICLE IN PRESS

EUROPEAN UROLOGY xxx (xxxx) xxx-xxx

available at www.sciencedirect.com journal homepage: www.europeanurology.com





Corrigendum

Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 2022]

Fabio Turco a,b,*, Andrew Armstrong c, Gerhardt Attard d, Tomasz M. Beer e, Himisha Beltran f, Anders Bjartell^g, Alberto Bossi^h, Alberto Brigantiⁱ, Rob G. Bristow^{j,k}, Muhammad Bulbul^l, Orazio Caffo^m, Kim N. Chiⁿ, Caroline Clarke^o, Noel Clarke^p, Ian D. Davis^q, Johann de Bono^r, Ignacio Duran^s, Ros Eeles^t, Eleni Efstathiou^u, Jason Efstathiou^v, Christopher P. Evans^w, Stefano Fanti^x, Felix Y. Feng^y, Karim Fizazi^z, Mark Frydenberg ^{aa,ab}, Dan George ^{ac}, Martin Gleave ^{ad}, Susan Halabi ^{ae}, Daniel Heinrich ^{ag}, Celestia Higano ^{ah}, Michael S. Hofman ^{ai}, Maha Hussain ^{aj}, Nicholas James ak, Rob Jones al, Ravindran Kanesvaran am, Raja B. Khauli an, Laurence Klotz ao, Raya Leibowitz^{ap,aq}, Christopher Logothetis ar,as,at</sup>, Fernando Maluf^{au,av}, Robin Millman aw, Alicia K. Morgans^f, Michael J. Morris ^{ax}, Nicolas Mottet ^{ay}, Hind Mrabti ^{az}, Declan G. Murphy ^{ba,bb}, Vedang Murthy bc, William K. Oh bd, Onyeanunam Ngozi Ekeke be, Piet Ost bf,bg, Joe M. O'Sullivan bh,bi, Anwar R. Padhani bj, Christopher Parker k, Darren M.C. Poon bl, Colin C. Pritchard bm, Danny M. Rabah bn, Dana Rathkopf bo, Robert E. Reiter bp, Mark Rubin bq,br, Charles J. Ryan bs, Fred Saad bt, Juan Pablo Sade bu, Oliver Sartor by, Howard I. Scher bo, bw, Neal Shore bx, Iwona Skoneczna by,bz, Eric Small a, Matthew Smith b, Howard Soule c, Daniel Spratt d, Cora N. Sternberg ce,cf, Hiroyoshi Suzuki cg, Christopher Sweeney ch, Matthew Sydes ci, Mary-Ellen Taplin ch, Derya Tilki cj,ck,cl, Bertrand Tombal cm, Levent Türkeri cn, Hiroji Uemura co, Hirotsugu Uemura cp, Inge van Oort cq, Kosj Yamoah cr, Dingwei Ye cs,ct, Almudena Zapatero cu, Silke Gillessen cv,cw,cx,cy,cz,†, Aurelius Omlin cy,da,†

^a Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; ^b Division of Medical Oncology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy; ^c Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA; ^d University College London Cancer Institute, London, UK; ^e Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA; ^f Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; ^g Department of Urology, Skåne University Hospital, Malmö, Sweden; ^h Genito Urinary Oncology, Prostate Brachytherapy Unit, Goustave Roussy, Paris, France; ⁱ Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy; ⁱ Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; ^k Christie NHS Trust and CRUK Manchester Institute and Cancer Centre, Manchester, UK; ¹ Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon; ^m Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy; ⁿ BC Cancer, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada; ^o Research Department of Primary Care & Population Health, Royal Free Campus, University College London, Rowland Hill St, London, UK; ^p The Christie and Salford Royal Hospitals, Manchester, UK; ^a Monash University and Eastern Health, Victoria, Australia; ^t The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Surrey, UK; ^s Department of Medical Oncology, Hospital

DOI of original article: https://doi.org/10.1016/j.eururo.2022.02.010

† These authors contributed equally.

https://doi.org/10.1016/j.eururo.2022.04.004

0302-2838/© 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Please cite this article as: F. Turco, A. Armstrong, G. Attard et al., Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 2022], Eur Urol (2022), https://doi.org/10.1016/ijeururo 2022 04 004

^{*} Corresponding author. Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland. Tel. +39 3927704290.

Universitario Marques de Valdecilla, IDIVAL, Santander, Cantabria, Spain; ^t The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK; "Houston Methodist Cancer Center, Houston, TX, USA; Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; University, of California Davis School of Medicine, Sacramento, CA, USA; * Policlinico S. Orsola, Università di Bologna, Bologna, Italy; ^y University of California, San Francisco, San Francisco, CA, USA; Institut Gustave Roussy, University of Paris Saclay, Villejuif, France; and Department of Surgery, Monash University, Melbourne, Australia; ab Prostate Cancer Research Program, Department of Anatomy & Developmental Biology, Faculty of Nursing, Medicine & Health Sciences, Monash University, Melbourne, Australia; ac Departments of Medicine and Surgery, Duke Cancer Institute, Duke University, Durham, NC, USA; ad Urological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada; ae Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA; ag Department of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway; an University of British Columbia, Vancouver, British Columbia, Canada; ai Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; aj Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA; ak The Institute of Cancer Research, London, UK; al Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; am Division of Medical Oncology, National Cancer Centre, Singapore; an Department of Urology and the Naef K. Basile Cancer Institute (NKBCI), American University of Beirut Medical Center, Beirut, Lebanon; ao Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; ap Oncology institute, Shamir Medical Center, Zerifin, Israel; af Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; ar Department of Genitourinary Medical Oncology, MD Anderson Cancer Centre, Houston, TX, USA; as Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, Athens, Greece; at David H. Koch Centre, Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Centre, Houston, TX, USA; au Beneficiência Portuguesa de São Paulo, São Paulo, SP, Brasil; av Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil; aw Patient Advocate, UK; ax Memorial Sloan Kettering Cancer Center, New York, NY, USA; ay University Hospital Nord St Etienne, St Etienne, France; az National Institute of Oncology, University Hospital, Rabat, Morocco; ba Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; bb Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia; bc Tata Memorial Centre, Mumbai, India; bd Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA; be Department of Surgery, University of Port Harcourt Teaching Hospital, Alakahia, Port Harcourt, Nigeria; bf Department of Radiation Oncology, Iridium Netwerk, Wilrijk (Antwerp), Belgium; bg Department of Human Structure and Repair, Ghent University, Ghent, Belgium; bh Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, Northern Ireland; bi Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland, UK; bj Mount Vernon Cancer Centre and Institute of Cancer Research, London, UK; bk Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK; bl Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, The Chinese University of Hong Kong, Hong Kong; bm Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; bn The Cancer Research Chair, College of Medicine, King Saud University, Riyadh, Saudi Arabia; bo Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; bp University of California Los Angeles, Los Angeles, CA, USA; bq Bern Center for Precision Medicine, Bern, Switzerland; br Department for Biomedical Research, University of Bern, Bern, Switzerland; bs Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; bt Centre Hospitalier de Université de Montréal, Montreal, Canada; bu Instituto Alexander Fleming, Buenos Aires, Argentina; by Tulane Cancer Center, New Orleans, LA, USA; by Department of Medicine, Weill Cornell Medical College, New York, NY, USA; ^{bx} Carolina Urologic Research Center, Myrtle Beach, SC, USA; ^{by} Rafal Masztak Grochowski Hospital in Warsaw, Warsaw, Poland; ^{bz} Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland; ca UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA; cb Massachusetts General Hospital Cancer Center, Boston, MA, USA; cc Prostate Cancer Foundation, Santa Monica, CA, USA; cd University Hospitals Seidman Cancer Center, Cleveland, OH, USA; ce Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA; cf Division of Hematology and Oncology, Meyer Cancer Center, New York Presbyterian Hospital, New York, NY, USA; cg Toho University Sakura Medical Center, Chiba, Japan; ^{ch} Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; ^{ci} MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK; cj Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; ck Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; cl Department of Urology, Koc University Hospital, Istanbul, Turkey; cm Cliniques Universitaires Saint Luc, Brussels, Belgium; cn Department of Urology, M.A. Aydınlar Acıbadem University, Altunizade Hospital, İstanbul, Turkey; co Yokohama City University Medical Center, Yokohama, Japan; cp Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan; ^{cq} Radboud University Medical Center, Nijmegen, The Netherlands; ^{ct} Department of Radiation Oncology & Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, FL, USA; cs Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; ct Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; cu Department of Radiation Oncology, Hospital Universitario de La Princesa, Health Research Institute, Madrid, Spain; ^{cv} Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; cw Universita della Svizzera Italiana, Lugano, Switzerland; cx Cantonal Hospital, St. Gallen, Switzerland; cy University of Bern, Bern, Switzerland; ^{cz} Division of Cancer Science, University of Manchester, Manchester, UK; ^{da} Department of Medical Oncology and Haematology, Cantonal Hospital, St. Gallen, Switzerland

The authors regret that Axel Heidenreich was added to the author list in error. The author list is now corrected as above, however the affiliations of remaining authors have been retained.

The authors would like to apologise for any inconvenience caused.